AVITA Medical Updates Expected First Quarter 2024 Revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/11/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
BTIG Downgrades Avita Medical Ltd. (RCEL) to Neutral
April 11, 2024 5:38 AM EDTBTIG analyst Ryan Zimmerman downgraded Avita Medical Ltd. (NASDAQ: RCEL) from Buy to Neutral.
The analyst comments "We downgrade RCEL shares to Neutral from Buy and remove our PT. RCEL announced 1Q24 rev. is expected to be $11.0M-$11.3M, ~26.1% - 28.1% below Cons. estimates and the guidance provided on the 4Q23 call of $14.8M - $15.6M. BTIG/Street expectations going into 1Q24 were $15.2M/$15.3M. Mgmt. noted the reduction in 1Q24 guidance was due to the slower-than-expected conversion rate of new accounts for full-thickness skin defects. We model flat product... More
